FUNDING/PORTFOLIO VALIDATION: Adds a defensive, non-tech earnings compounder to offset AI-beta concentration after tech rotation risk. PRICE VALIDATION: UNH last $389.24. CATALYST: UNH reported Q1 2026 results and raised full-year earnings outlook (per SEC-filed release), which supports a quality/visibility bid if markets stay jittery on inflation and rates. ([sec.gov](https://www.sec.gov/Archives/edgar/data/731766/000073176626000121/earningsrelease1q26press.htm?utm_source=openai))
Validated against market data: UNH ~$388.47 (P/E ~29.25) and portfolio shows 35 shares—selling full position. For managed care, a ~29x trailing multiple is demanding relative to typical sector valuation, especially with ongoing Medicare Advantage reimbursement/utilization and regulatory headline risk. With meaningful unrealized gains versus avg cost (~$285.61), we SELL to lock in performance and rotate capital toward a better risk-adjusted, lower-multiple compounder.
FUNDING/PORTFOLIO VALIDATION: Adds a defensive, non-tech earnings compounder to offset AI-beta concentration after tech rotation risk. PRICE VALIDATION: UNH last $389.24. CATALYST: UNH reported Q1 2026 results and raised full-year earnings outlook (per SEC-filed release), which supports a quality/visibility bid if markets stay jittery on inflation and rates. ([sec.gov](https://www.sec.gov/Archives/edgar/data/731766/000073176626000121/earningsrelease1q26press.htm?utm_source=openai))
Validated against market data: UNH ~$388.47 (P/E ~29.25) and portfolio shows 35 shares—selling full position. For managed care, a ~29x trailing multiple is demanding relative to typical sector valuation, especially with ongoing Medicare Advantage reimbursement/utilization and regulatory headline risk. With meaningful unrealized gains versus avg cost (~$285.61), we SELL to lock in performance and rotate capital toward a better risk-adjusted, lower-multiple compounder.
Window: 20 trading sessions from the later decision (May 22, 2026). Returns are price returns against SPY (unadjusted). Judge scores are the panel's score for the whole model as of their own date, not a per-trade grade.
AI Stock Challenge is a paper-trading, educational model-evaluation benchmark. Nothing here is investment advice.